Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity.
GLP-1受體激動劑在達到減重和改善超重和肥胖人群心血管結果中的作用。
J Am Heart Assoc 2023-08-01
Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases.
腸道和胰臟荷爾蒙療法的協同組合:代謝性疾病治療的進展。
Endocrinology 2023-11-11
Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study.
GLP-1激動劑與生活方式指導在肥胖與糖尿病前期管理中的混合方法有效性:RWE回顧性研究。
Metabol Open 2024-05-04
Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.
生活方式和胰高血糖素樣肽-1受體激動劑在肥胖症、2型糖尿病和脂肪肝疾病中減重的作用。
Aliment Pharmacol Ther 2024-05-30
Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists.
能量平衡與肥胖:胰高血糖素樣肽-1 受體激動劑的新興角色。
Curr Opin Clin Nutr Metab Care 2024-08-16
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.
肥胖中 GLP-1 生理學及基於促胰島素的藥物在慢性體重管理中的發展。
Nat Metab 2024-08-19
Efficacy of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Weight Loss Management in Non-Diabetic Patients.
非糖尿病患者使用胰高血糖素樣肽-1 (GLP-1) 受體激動劑進行減重管理的療效。
Cureus 2024-08-21
Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs.
服用 GLP-1 和雙重 GIP/GLP-1 受體激動劑患者的飲食攝取:敘述性回顧及研究需求討論。
Obes Pillars 2024-08-23